GCIPolarean Imaging taps Dr. Chase Hall as Chief Medical Advisor to advance Xenon MRI technology
() , a commercial-stage MRI technology company, announced the appointment of Chase Hall, MD as its Chief Medical Advisor. Polarean is best known for its proprietary Xenon MRI technology XENOVIEW, which uses hyperpolarised Xenon Xe 129 to illuminate hidden lung diseases non-invasively.
Hall is an associate professor of pulmonary, critical care and sleep medicine at the University of Kansas Medical Center in the Division of Pulmonary and Critical Care. He also serves as Associate Director at the University of Kansas Interstitial Lung Disease and Rare Lung Disease Clinic.
Hall's research focus has been on establishing imaging biomarkers in respiratory disease utilising Xenon MRI. He is a member of the Xenon MRI Clinical Trials Consortium, a growing collaboration of 13 clinical research sites, focused on the standardisation of Xenon imaging protocols for multi-center clinical trials.
Dr. Chase Hall commenting: "For several years, I have been deeply interested in the potential of Xenon MRI to assist pulmonary clinicians and the patients we treat. There is a significant unmet need in pulmonary medicine for imaging technology that can better characterise disease, monitor response to therapy, and guide interventional procedures. I am excited to join Polarean to help guide the clinical development and implementation of this unique technology in pulmonary medicine."
View from Vox
Polarean marks a valuable addition to its R&D team in Dr. Chase Hall who is a leading expert in both pulmonary medicine and Xenon MRI technology. Hall's professional goals have aligned with Polarean's in expanding Xenon MRI to more clinical and research sites. In fact, he hails from the renowned University of Kansas Medical Center, which recently signed a deal with Polarean to replace its research hyperpolariser for a new clinical-grade system using Polarean's Xenon MRI technology.
Polarean's Xenon MRI platform promises to revolutionise medical imaging with the ability to illuminate hidden diseases non-invasively. This can enable early intervention and significantly improve patient outcomes. In addition to the University of Kansas Medical Center, current customers include the world-renowned Cincinnati Children's Hospital Medical Center, the University of Virginia Health System, University of Missouri Health Care, and University of Alabama at Birmingham Hospital.
As CMA, Hall will leverage his experience to guide Polarean's clinical development strategy as well as medical education initiatives with fellow clinicians and professional societies. He will also maintain his clinical practice, providing insight to help Polarean address unmet medical needs in pulmonary care.
Polarean has made significant commercial strides in advancing its Xenon MRI technology XENOVIEW, notably the receipt of a new reimbursement C-code from US Medicare with a payment range of $1,201 to $1,300, enhancing the technology's economic viability for hospitals.
's recent US$10m fundraise extended its cash runway into Q1 2026. Management expects US$2.5m of revenues in FY24 while active discussions are ongoing with more medical institutions as XENOVIEW sales continue to gain momentum. In FY23, narrowed its pre-tax loss to US$11.9m from $13.9m LY. By end of FY24, should have a total installed clinical base of 5-7 systems with sites performing 3-4 scans/week, enabling them to earn a positive ROI on XENOVIEW.
If takeup continues its current trajectory, by end of 2025 's total installed clinical base should be 12-14 systems with scans performing 5-6 scans/week and revenues of US$5-6m. Profitability would then be expected by 2027.
Follow News & Updates from Polarean Imaging:
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.